The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Fully human therapeutic monoclonal antibodies.
Abstract
Monoclonal antibody (mAb) therapy has been facilitated by a number of technologic advances over the past 30 years. Whereas hybridoma development of murine mAbs was requisite for the development of mAbs as drugs, the inherent immunogenicity of rodent sequences in humans has presented obstacles to the clinical application of mAbs. Sensitization to mAb therapeutics poses significant risk to the patient and may blunt the efficacy of these therapies. The advent of chimeric antibodies lessened but did not eliminate the rodent content of mAbs; thus, immunogenicity remained a concern. Further elimination of rodent sequences enabled the production of humanized mAbs, followed by current technology using phage display and, finally, transgenic mice technology, which allows for the generation of fully human therapeutic mAbs. The reduced immunogenicity of this new generation of mAbs is expected to enhance efficacy, safety, and ease of use. In addition to providing replacements for existing mAb drugs, new technologies have greatly facilitated the optimization and modification of mAbs, opening numerous therapeutic avenues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Denosumab and numerous other fully human therapeutic antibodies have been made in transgenic mice, wherein their murine Ig genes have been deleted and replaced with human orthologs (431, 432).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [431]
In the citing paper
“Another potential advantage of a fully human anti-RANKL antibody is the low potential for immune responses (431), a theoretical attribute that has been borne out in clinical trials with denosumab.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [431]
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200
Smith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Phage antibodies: filamentous phage displaying antibody variable domains
McCafferty, J., Griffiths, A. D., Winter, G. P., & Chiswell, D. J. (1990) · Nature · doi:10.1038/348552a0 · Cited by 2,427
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Assche, G. V., Haens, G. D., Carbonez, A., & Rutgeerts, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,012
Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,610
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., & Winter, G. P. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90498-u · Cited by 1,605
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. P. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,565
Single-Chain Antigen-Binding Proteins
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S., Lee, T. T., Pope, S. H., Riordan, G. S., & Whitlow, M. D. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,522
McCune, J. M., Namikawa, R., Kaneshima, H., Shultz, L. D., Lieberman, M., & Weissman, I. L. (1988) · Science · doi:10.1126/science.2971269 · Cited by 1,404
Research works printed but not linked: 5
- Skamene, 1971, Clin Exp Immunol, 8, 195
- Hale, 1983, Mol Biol Med, 1, 321
- Yokota, 1993, Cancer Res, 53, 3776
- Adams, 2001, Cancer Res, 61, 4750
- Milenic, 1991, Cancer Res, 51, 6363
Cited by
Sorted by citations
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Targeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,362
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Recent advances in large-scale production of monoclonal antibodies and related proteins
Shukla, A. A., & Thömmes, J. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.02.001 · Cited by 601
Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., Thomas, A., Tjulandin, S., Zhang, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70118-4 · Cited by 473
Metadata
- Authors
- Weiner, L. M.
- Affiliations
- Fox Chase Cancer Center (US)
- Corresponding author
- Weiner, Louis M
- ORCID
- Weiner, Louis M
- Venue
- Journal of Immunotherapy
- Published
- 2006-01
- Volume
- 29
- Issue
- 1
- Pages
- 1-9
- ISSN
- 1524-9557 (ISSN-L)
- OpenAlex
- W1971456299
- Cited by
- 164
- References
- 36
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 5 · 2019: 7 · 2018: 4 · 2017: 1 · 2016: 5 · 2015: 9 · 2014: 8 · 2013: 9 · 2012: 17
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Immunotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 50633, CA06926, R01CA050633)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- monoclonal antibodies, fully human antibodies, immunogenicity, chimeric antibodies, humanized monoclonal antibody, transgenic mice, phage display, hybridoma technology, antibody engineering, therapeutic antibodies
- MeSH terms
- Animals, Antibodies, Monoclonal, Genetic Engineering, Humans, Mice, Transgenic, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
